Articlenpj aging2026
Astaxanthin improves myogenicity of aged skeletal muscle progenitor cells in a sexually dimorphic manner.
Article in npj aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The metabolic-epigenetic landscape of aging: interplay between histone acetylation, lactylation, and glycation.Frontiers in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Age-related declines in skeletal muscle health are a major contributor to reduced mobility and development of sarcopenia in the elderly, yet effective interventions to prevent or reverse these declines are not fully optimized. Nutritional strategies to support muscle health in aging populations may be beneficial for improving muscle strength and function. In this study, we explored the effects of astaxanthin (AX), a naturally occurring antioxidant, on aged human muscle progenitor cells (hMPCs). Our findings reveal that AX enhanced proliferation and myogenic commitment of aged hMPCs, with a more pronounced effect in male hMPCs compared to female hMPCs. This dimorphism may be linked to differences in reactive oxygen species (ROS)-scavenging and effects on mitochondrial function. Other hallmarks of aging including DNA damage and cellular senescence showed differing effects of AX treatment. However, NRF2 and SIRT3 increased with AX treatment in both male and female hMPCs. This was accompanied by increased SIRT3 mitochondrial expression in males but not females, suggesting the NRF2-SIRT3 axis as a key driver of myogenicity and potential source of sexual dimorphism in response to AX. These results suggest sex-specific effects of AX in modulating aged hMPC behavior and pose a potential therapeutic strategy for combating age-related muscle decline.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.